FIELD: organic chemistry, steroids, pharmacy. SUBSTANCE: invention describes steroid compounds of the general formula (I) where: a) R4 means 3'-methyl-but-3'-ene-1'-inyl or cyclopro-pylethynyl; R5 means methyl; R6 means acetyl; dotted line means a single bond; b) R4 means trifluoromethyl-group; R5 means methyl; R6 means acetyl; dotted line means a single or a double bond and in the case when this bond is a single one, R6 is hydroxyacetyl and R5 is hydrogen atom then R4 can mean fluoromethyl-group; c) R4- means ethynyl; R5 means methyl; R6 means hydroxymethyl or hydroxyacetyl; dotted line means a single bond, or their physiologically acceptable 21-esters, 3,20-diesters or 3,21-diesters or where: a) R6 means hydroxyacetyl; R5 means hydrogen atom in the case when R4 is trifluoromethyl-group and compound is presented as sodium 21-hemisuccinate; b) R6 means hydroxyacetyl; R5 means methyl and R4 can mean the following values: hydrogen atom in the case when compound is presented as bis-hemisuccinate; ethynyl in the case of 21-hemisuccinate; trifluoromethyl-group in the case of sodium 21-hemifumarate, methyl-21-succinate, 21-propionate; and c) R4 means methyl; R5 means methyl; R6 means isopropylideneaminoethanol being dotted line means a single bond. Compounds of the formula (I) show ability to modulate excitability of GRC complex and therefore they can be used for treatment of patients with stresses, anxiety state, epileptic attack, mood disorders, premenstrual syndrome and post-delivery depression and for induction of anesthesia also. EFFECT: improved method of treatment and induction, valuable medicinal properties. 15 cl, 8 tbl, 31 ex
Title |
Year |
Author |
Number |
NEUROACTIVE STEROIDS, PHARMACEUTICAL PREPARATION, METHOD OF TREATMENT AND PROPHYLAXIS OF DIFFERENT DISORDERS, METHOD OF SLEEP INDUCTION AND METHOD OF ANESTHESIA INDUCTION WITH THEIR USING, METHOD OF MODULATION OF COMPLEX RECEPTOR GABAA-CHLORIDE IONOPHORE |
1996 |
- Lehn Nensi K.
- Fik Dehvid B.
- Khogenkehmr Derk Dzh.
- Jupehzehnaj Rehjvindra B.
|
RU2194712C2 |
NEW STEROID COMPOUNDS SHOWING HIGHER WATER SOLUBILITY AND METABOLISM RESISTANCE, AND METHODS FOR PREPARING THEM |
2007 |
- Behkstrem Torb'Ern
- Ragagnin Dzhinna
|
RU2458065C2 |
3α-ETHYNYL, 3β-HYDROXY, 5α-PREGNAN-20-OXIME FOR USE IN TREATING CNS DISORDERS |
2016 |
- Ragagnin Gianna
- Backstrom Torbjorn
|
RU2712786C2 |
ORGANIC COMPOUNDS |
2019 |
- Vanover, Kimberly
- Li, Peng
- Davis, Robert
- Qiao, Yupu
|
RU2809023C2 |
DERIVATIVES OF 11,21-BISPHENYL-19-NORPREGNANE, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION AND METHOD OF ITS PREPARING |
1995 |
- Gebkhar Ronal'D
- Van Der Vort Khendrikus Adrianus Antonius
|
RU2152952C2 |
METHOD OF PRODUCING 3β-ACETOXY-17α-HYDROPEROXY-16α-METHYLPREGNANES FROM Δ-20-KETOSTEROIDS AND METHOD OF PRODUCING 3β-ACETOXY-17α-HYDROXY-16α-METHYLPREGNANES USING 3β-ACETOXY-17α-HYDROPEROXY-16α-METHYLPREGNANES |
2009 |
- Savinova Tat'Jana Stepanovna
- Lukashev Nikolaj Vadimovich
- Beletskaja Irina Petrovna
|
RU2418805C1 |
METHOD OF STEREO-SPECIFIC REDUCTION OF SAPOGENINE-3 |
2003 |
- Ganning Filip Dzhejms
- Tiffin Peter Dehvid
|
RU2326890C2 |
ANDROSTANES |
1995 |
- Dehvid L. Berliner
- Natan V. Adams
- Kliv L. Dzhennings-Vajt
|
RU2160740C2 |
ANDROSTEN(ANE) (ONE) DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF, METHODS OF PREPARATION THEREOF, AND METHOD OF MEDICAL TREATMENT |
1994 |
- Behchelor Kennet Uil'Jam
- Fraj Stiven Vernon
|
RU2144037C1 |
DERIVATIVES OF 19-NORPREGNENE, PHARMACEUTICAL COMPOSITION, COMPOUNDS |
1997 |
- Alan Piasko
- Zhan Ljafaj
- Remi Delansorn
- Zhak Pari
- Zhan-Klod Paskal'
|
RU2166509C2 |